CytomX Q1 revenue $23.5M vs $9.0M YoY; cash $204.5M; pipeline advances

CytomX Therapeutics, Inc.

Revenue $23.5M in Q1 2023, up from $9.0M Q1 2022, driven by BMS project progress, Astellas milestone, and AbbVie termination revenue recognition.
Cash, equivalents and investments $204.5M at Mar 31, 2023, versus $193.7M at Dec 31, 2022; includes $35M Moderna upfront and $5M Astellas milestone.
AbbVie terminated CD71 collaboration; CX-2029 not advanced to additional studies; CytomX evaluating full rights acquisition and next-gen CD71 strategies.
BMS advanced BMS-986288 (anti-CTLA-4 Probody) from Phase 1 to Phase 2 as lead next-gen CTLA-4 program.
Marcia Belvin promoted to Chief Scientific Officer; IND filings for CX-2051 and CX-801 targeted for H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CytomX Therapeutics, Inc. reported financial results for the three months ended March 31, 2023.

Period: the three months ended March 31, 2023
Result: reported results

Exact text from the filing

On May 9, 2023, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results as of and for the three months ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

CytomX Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-019674

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.